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Abstract: Patients with type 2 diabetes mellitus (T2DM) and/or cardiovascular disease (CVD), condi-
tions of hyperinsulinaemia, have lower levels of osteocalcin and bone remodelling, and increased
rates of fragility fractures. Unlike osteoporosis with lower bone mineral density (BMD), T2DM bone
fragility “hyperinsulinaemia-osteofragilitas” phenotype presents with normal to increased BMD.
Hyperinsulinaemia and insulin resistance positively associate with increased BMD and fragility frac-
tures. Hyperinsulinaemia enforces glucose fuelling, which decreases NAD+-dependent antioxidant
activity. This increases reactive oxygen species and mitochondrial fission, and decreases oxidative
phosphorylation high-energy production capacity, required for osteoblasto/cytogenesis. Osteocytes
directly mineralise and resorb bone, and inhibit mineralisation of their lacunocanalicular space via
pyrophosphate. Hyperinsulinaemia decreases vitamin D availability via adipocyte sequestration,
reducing dendrite connectivity, and compromising osteocyte viability. Decreased bone remodelling
and micropetrosis ensues. Trapped/entombed magnesium within micropetrosis fossilisation spaces
propagates magnesium deficiency (MgD), potentiating hyperinsulinaemia and decreases vitamin D
transport. Vitamin D deficiency reduces osteocalcin synthesis and favours osteocyte apoptosis. Carbo-
hydrate restriction/fasting/ketosis increases beta-oxidation, ketolysis, NAD+-dependent antioxidant
activity, osteocyte viability and osteocalcin, and decreases excess insulin exposure. Osteocalcin is
required for hydroxyapatite alignment, conferring bone structural integrity, decreasing fracture risk
and improving metabolic/endocrine homeodynamics. Patients presenting with fracture and normal
BMD should be investigated for T2DM and hyperinsulinaemia.
Keywords: hyperinsulinaemia; beta hydroxybutyrate; osteoporosis; type 2 diabetes; fragility
fractures; bone mineral density; osteocalin; vitamin D; collagen; hydroxyapatite
1. Introduction
In 2010, 3.5 million fragility fractures were sustained in 27 European Union countries,
with an estimated economic burden cost of €37 billion. It is predicted that by 2025, the
economic burden will continue to increase by 25% [1]. Further, in the largest five European
Union countries plus Sweden (EU6), fragility fractures are predicted to increase from
2.7 million in 2017 to 3.3 million by 2030, with a €37.5 billion annual fracture-related cost in
2017, expected to increase by 27% in 2030 [2].
Increased fragility fractures are well documented in patients with type 2 diabetes
mellitus (T2DM), a condition of chronic hyperinsulinaemia [3–7]. Decreased skeletal bone
mineral density (L-BMD) is the phenotype of “classical” osteoporosis [8,9]. A higher BMD
is considered to confer greater bone strength (fracture resistance). However, the T2DM bone
fragility phenotype more often presents with normal to increased BMD (H-BMD) [7,9–14],
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and positively tracks with increased fracture risk [4,5,7,12,15]. In a cross-sectional non-
intervention study of 146 Caucasian non-diabetic postmenopausal women with a mean age
of 60 ± 2.7 years, HOMA-IR was found to be positively associated with volumetric bone
mineral density (vBMD) [11]. In addition, increased insulin resistance (IR) and treatment
with exogenous insulin therapy is positively associated with higher BMD and increased
fragility fractures. A study following 5994 T2DM males ≥ 65 years of age, found a higher
non-vertebral fracture risk in those using insulin (HR 1.74, 95% CI 1.13, 2.69) who also had
a higher BMD [15]. Furthermore, in a population-based matched cohort study investigating
primary care records of 2979 insulin users and 14,895 non-users, T2DM patients exposed to
insulin therapy to manage glycaemia were found to have a 38% excess fracture risk [12]. In
both H-BMD-associated T2DM “osteofragilitas” (bone fragility) and L-BMD osteoporosis
phenotypes, there is an increase in bone fragility and a loss in tensile and/or torsion
strength, and bone ductility, resulting in higher rates of fractures.
Hyperinsulinaemia drives the pathogenesis of T2DM, which may precede hypergly-
caemia by up to 24 years [6,16]. Hyperinsulinaemia decreases osteoblastogenesis and prop-
agates poorer-quality collagen production, a problem further compounded by hypergly-
caemia increasing glycation damage on new or existing bone collagen. Hyperinsulinaemia
drives chronic osteocyte distress via excess ceramide synthesis, which increases cellular
reactive oxygen species (ROS) [17–20], leading to a unique type of mineralisation within
their lacunae, coined by Bell, Kayser and Jones as “living fossilisation” [21–25]. Concomi-
tantly, hyperinsulinaemia decreases osteoclastogenesis, thus impeding the bone resorption
needed to enable homeodynamic bone remodelling—a marker of good health [7,26] —and
this results in a form of hyperinsulinaemia-hyperglycaemia pseudo-osteopetrosis. Com-
bined, these hyperinsulinaemia-driven effects result in the increased bone mineral density
seen in people with T2DM.
Osteocytes are the backbone of bone health, and consequently major players in whole-
body metabolism [27]. Osteocytes are able to directly mineralise and resorb bone and are
central mediators in the regulatory control of osteoblasts and osteoclasts [28–36]. Chronic
hyperinsulinaemia diminishes the replenishment of osteocytes and drives the living fossili-
sation of the ones in existence, leading to the loss of the osteocyte’s dynamic orchestration
of bone remodelling [21–25,37]. We propose chronic hyperinsulinaemia provides a plausi-
ble explanation, a unifying theory of the mechanisms of action, for the increased BMD and
bone fragility “osteofragilitas”, that leads to the increased fracture rates seen in the T2DM
bone phenotype.
2. Osteocytes: Mediators of Bone Remodelling and Metabolic Heath
Within the adult skeleton, osteocytes comprise 90% to 95% of the total bone cells [37].
Osteocytes are terminally differentiated cells from the osteoblast lineage. They are the
heavyweight lifters in the living dynamic bone tissue that not only provides a physical
scaffold for the body, but is also fundamental in endocrine regulation and whole-body
metabolism [14,38,39]. Osteocytes embed within the bone after collagen formation by
osteoblasts, of which some of these osteoblasts are fated to differentiate into the embedding
osteocytes [37]. The osteocytes, along with their neighbouring osteoblasts, continue to form
mineralised bone onto the collagen scaffold, in the process forming the hydroxyapatite
lacuna chamber around the embedding osteocytes [27]. Continual morphological changes
take place in the process of osteocytogenesis, leading to cells that bear little resemblance
in structure to their predecessors, appearing visually more like neurons. Osteocytes have
on average 50, and up to 100 dendrites, extending through highly connected intricate
tunnels, called the canaliculi. The canaliculi are formed and maintained by the occupying
osteocytes [40], and enable physical connection to other osteocytes and to the outside
surface of bone, to osteoblasts, osteoclasts and the vasculature [41].
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The lacunocanalicular system is a fluid-filled space, separated from the mineralised
component of bone and maintained by the resident osteocytes [22]. The osteocytes are
the workhorse physical mechano-sensors and mediators of bone remodelling, sensing
and responding to mechanical stress via their strategic distribution and network of a
vast number of connected dendritic processes that enable intercellular communication.
Their network forms the essential antenna to detect fluid shear stress, which enables the
translation of mechanical stimuli into biochemical messages. Osteocytes, in turn, feed these
signals forward via autocrine and paracrine mechanisms, to elicit homeostatic adaptive
responses, from regulating bone remodelling in order to provide sensitive and continual
changes to whole-body mineral needs, to effecting distant organ responses via endocrine
signalling [22,41].
3. Dendritic Connectivity Is Essential for Function and Viability
Osteocytes connect to one another via their dendritic processes which form the
osteocyte-lacunocanalicular network, and their health and viability are dictated by their
dendritic connectivity [41,42]. A compromise in osteocyte health diminishes their ability to
actively inhibit mineralisation of their pericellular space [25,28], consequently reducing
their connectivity. This further compromises the health of deeper osteocytes that become
cut off from receiving nutrients which are no longer able to be delivered through fluid
movement via the canalicular tunnels. Furthermore, osteocyte connectivity is required for
the transduction of load-induced fluid flow that enables their mechanical sensory system
to decrease apoptosis and increase osteocytogenesis [43]. Maintenance of dendritic con-
nectivity allows osteocyte-directed regulation of osteoblasts and osteoclasts, in addition to
their own capacity to directly resorb bone [29,30,34–36].
It is highly likely that osteocytes rather than osteoclasts are responsible for bone
resorption in the basal condition, as a function of whole-body mineral homeostasis, and that
osteoclast bone resorption serves to function in the acute action/need/stress response [34].
Osteocytes from lactating mice have been shown to express markers thought to be specific
to osteoclasts. Their osteocyte lacunae were found to be enlarged, suggesting localised
bone resorption, providing evidence of osteocytic-osteolysis [44]. Patients with T2DM have
decreased levels of carboxy-terminal collagen crosslinks (CTX) bone resorption marker,
indicating a lower bone turnover [13]. Osteocytes regulate both osteoblast and osteoclast
differentiation and function, and are thus master regulators of dynamic bone remodelling,
a function of healthy physiology (Figure 1) [45].
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Figure 1. Schematic representation showing the dynamic role of osteocytes in the regulation of healthy and dysregulated 
bone. Beta-adrenergic receptor (Adr𝛽2), hydroxyapatite (HA), osteocalcin (OCN), osteoprotegerin (OPG), receptor activa-
tor of nuclear factor kappa-𝛽 ligand (RANKL), and reactive oxygen species (ROS). Red lines indicate hyperinsulinaemia-
driven pathology pathways. Healthy physiology indicated with blue and purple lines. 
Figure 1. Schematic representation showing the dynamic role of osteocytes in the regulation of healthy and dysregulated
bone. Beta-adrenerg ceptor (Adrβ2), hydroxyapatite (HA), steocal in (OCN), osteopr tegerin (OPG), receptor ac ivator
of nuclear factor kappa-β ligand (RANKL), and reactive oxygen species (ROS). Red lines indicate hyperinsulinaemia-driven
pathology pathways. Healthy physiology indicated with blue and purple lines.
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4. Hyperglycaemia Increases Advanced Glycation End-Product Formation in Bone Collagen
The anabolic hormone insulin is required at the basal level for healthy bone forma-
tion [3]. However, chronic hyperinsulinaemia surpasses this threshold in a dose and
duration manner. When coupled with hyperglycaemia, it results in the production of
poorer-quality, more rigid collagen and glycation damage of existing collagen [46,47]. To-
gether, they drive increasing BMD by promoting skeletal mineral acquisition that is fragile
in structure [22,48]. Hyperglycaemia and hyperinsulinaemia increase advanced glycation
end-product (AGE) formation. Increased glycation on fibrillar collagen negatively affects
bone quality [14]. In human tissue, the most abundant AGE is glucosepane, a lysine–
arginine cross-linking, that forms the major AGE in bone type 1 collagen. Hyperglycaemia
is one of the leading causes of AGE formation, affecting the structural and biochemical
properties of protein binding sites, rendering them unrecognisable to other proteins and
enzymes [47].
Hyperglycaemia-driven AGE formation of glucosepane in bone collagen causes a
decrease in viscoelasticity and increases the production of a stiffer collagen, resulting
in negative effects on the mechanical properties of load-bearing collagen in bone. This
causes bone toughness to decrease, while a greater accumulation of AGE in bone results in
increased fracture risk [47]. Furthermore, an increase in stiffer/rigid collagen production
occurs due to increased glycation effects on the vasculature, leading to increased hypoxia
in the microenvironment [14]. Hypoxia then compromises the osteoblasts’ capacity to gen-
erate sufficient ATP for collagen synthesis and for differentiation into osteocytes (Figure 1).
Both of which are very energy intensive processes, requiring an efficient mitochondrial
capacity to generate ATP via oxidative phosphorylation (OxPhos) [49–52]. In addition,
hyperinsulinaemia and hyperglycaemia inhibit beta-oxidation, whilst increasing mitochon-
drial (mt) reactive oxygen species (ROS) formation [53]. This leads to increased H2O2
production, causing damage to intracellular protein synthesis machinery and consequently
synthesis of poorer quality collagen. The typical methodology of assessing bone quality is
via dual x-ray absorptiometry, however, this method is unable to detect the collagen aspect
of bone quality [14]. As a result, there is an increased frequency in missing early detection
of hyperinsulinaemia-hyperglycaemia osteofragilitas fracture risk, which typically does
not present with L-BMD. This suggests that BMD alone is a poor proxy/diagnostic marker
for fracture risk in hyperinsulinaemic individuals.
Hyperinsulinaemia “enforces” cellular glucose substrate fuelling [54], and downregu-
lates beta-oxidation by increasing intracellular ceramide production [20]. Excess ceramide
production compromises mtOxPhos capacity, by increasing dynamin-related protein 1
(Drp1) synthesis. Drp1 functions to increase mitochondrial fission, in addition to increasing
the production of mtROS such as: superoxide (O2−), hydroxyl radical (−OH) and hydrogen
peroxide (H2O2) [17,20,55]. Concomitantly, ATP production from glucose oxidation re-
duces the intracellular pool of nicotinamide adenine dinucleotide (NAD+), consuming four
NAD+ in the production of two acetyl moieties, in comparison to beta-oxidation, ketolysis
or oxidation of acetoacetate, which consume two, one and zero respectively (Figure 2) [56].
Thus, ATP synthesis that is increasingly reliant on glucose oxidation, negatively impacts
the availability of NAD+.
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Figure 2. Schematic representation of hyperinsulinaemia effects on cellular oxidative state, and bone homeodynamics.
Acetoacetate (AcAc), adenosine triphosphate (ATP), advanced glycation end-products (AGE), beta-adrenergic receptor 2
(AdrB2), beta-hydroxybutyrate (BHB), heparan sulphate (HS), heparan sulphate proteoglycan (HSPG), hydrogen peroxide
(H2O2), hyperinsulinaemia (HI), insulin receptor (InsR), isocitrate dehydrogenase 2 (Idh2), forkhead box O1 (FoxO1),
glutathione oxidised form (GSSG), glutathion reduced form (GSH), lysine 68 (K68), magnesium (Mg), manganese superox-
ide dismutase 2 (MnSOD2), nicotinamide adenine dinucleotide (NAD+), nicotinamide adenine dinucleotide phosphate
(NADP+), nuclear factor-kB (NF-kB), osteocalcin carboxylated (Gla-OCN or cOCN), osteocalcin un(der)carboxylated (Glu-
OCN or ucOCN), osteoprotegerin (OPG), oxidative phosphorylation (OxPhos), receptor activator of nuclear factor-kB
ligand (RANKL), reactive oxygen species (ROS), sirtuin 3 (SIRT3), superoxide (O2−), tumour necrosis factor α (TNFα), T
cell immune regulator 1 (Tcirg1), tryptophan hydroxylase (Tph), vitamin D (D3), and vitamin K (K).
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Sirtuin-3 (SIRT3) regulates the synthesis of endogenous antioxidant enzymes such
as mitochondrial manganese superoxide dismutase (MnSOD2) and NADPH-dependent
production of reduced glutathione (GSH) [56,57]. An increased reliance on glucose fuelling
and its effect on NAD+ availability, leads to a reduction in SIRT3 activity, since SIRT3 is
NAD+ dependent. This in turn decreases signals for the transcription and synthesis of
MnSOD2 and GSH [56,57]. Furthermore, hyperinsulinaemia, diminishes the oxidative
buffering capacity of the cellular redox antioxidant GSH [58]. Beta-oxidation activity
dramatically increases in osteoblasts as they mature. If beta-oxidation is diminished and/or
inhibited, metabolic demand cannot be met, resulting in a decrease in precursor cellular
differentiation capability, as osteoblastogenesis and osteocytogenesis are energy intensive
processes [49,51,52]. Bone neither stores nor synthesises any significant amount of fat.
Thus, fatty acids delivered via chylomicron remnants (CR) and low-density lipoproteins
(LDL) to bone are more likely to be used for ATP synthesis via beta-oxidation [51].
5. Hyperinsulinaemia Increases Osteocyte Mitochondrial Fission and Disassociation
from the Endoplasmic Reticulum
Healthy osteocytes are able to transfer their functional mitochondria to neighbour-
ing distressed osteocytes via their physically connected dendrites [42]. Mitochondrial
transfer between osteocytes declines with age and with decreased dendritic connec-
tions [22,28,42,59]. Osteocytic rescue of their distressed neighbours via mitochondrial
transfer is dependent on their mitochondria associating with the endoplasmic reticulum
(ER) and on their dendrite connectivity, which requires the maintenance of their lacuno-
canalicular tunnels via inhibiting excessive mineralisation [21,29,31,42]. Hyperinsulinaemia
increases mtROS production via ceramide synthesis which increases mitochondrial fission
and ER stress [20,60]. This results in less mitochondrial fusion, which is necessary for
beta-oxidation, and also leads to decreasing the osteocytes’ capability to transfer mito-
chondria to adjacent distressed osteocytes. This osteocytic mitochondria transfer process
is dependent on mitochondrial association with the ER (ER-mito), driven by the protein
guanosine triphosphatase mitofusin 2 (Mfn2), which localises to the outer mitochondrial
membrane (OMM), enabling the tethering of the mitochondrion to the ER [42]. Reductions
in Mfn2 expression leads to reductions in mitochondrial fusion and distribution, which fur-
ther decreases the ability of healthier osteocytes to rescue their distressed neighbours [22].
Hyperinsulinaemia increases the Drp1:Mfn2 ratio. As a result this favours mitochondrial
fission and ER-mito disassociation, leading to decreased OxPhos ATP synthesis and in-
creased mtROS production [20,61]. Interestingly, osteocytes are under a form of social
control, as they must receive signals from other cells for their survival, which is reliant on
their connectivity [48]. A fall in the number of viable osteocytes or dendritic connections,
below an essential minimum number (a threshold), or excessive lacunocanalicular min-
eralisation, may result in a severely compromised osteocyte-network signal transduction
capacity, which in turn would impair dynamic bone remodelling [48]. Osteocytes actively
maintain the lacunae-canalicular space, enabling fluid flow dynamics that ensures the
provision of nutrients and signalling molecules such as growth factors and cytokines, in
addition to facilitating the removal of waste. This is essential for the deeper embedded
osteocytes and osteoblasts, to remain viable and function healthily [29]. Chronic hyper-
insulinaemia may contribute to significant detrimental remodelling of dendrites and the
lacunae-canalicular space, where the number (threshold) of osteocytes affected may result
in a profoundly negative outcome.
6. MnSOD2 and SIRT3 Required for Osteoblastogenesis and Osteocytogenesis
Chronic hyperinsulinaemia and hyperglycaemia drives the pathogenesis of T2DM,
chronic kidney disease (CKD) and atherosclerosis, conditions that are associated with in-
creased rates of fractures independent of L-BMD. Hyperinsulinaemia with hyperglycaemia
likely causes a decrease in osteocyte population and/or functional capacity leading to
hyperinsulinaemia-osteofragilitas [4,38,39,62,63]. Glucose restriction increases osteoblast-to-
osteocyte specification, and conversely hyperglycaemia reduces osteoblast gene expression
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of Osx, Bglap or Dkk1, leading to a reduction in osteocytogenesis [37]. Furthermore, hyper-
glycaemia decreases osteocyte connectivity and population. Viable osteocytes are needed to
signal pre-osteoblastogenesis and osteocytogenesis. Therefore, hyperglycaemia’s negative
impact on osteocyte numbers and dendritic connectivity, may result in a detrimental impact
on the maintenance of the osteocyte-lacunocanalicular network. As a result, this would
impair the osteocytes’ role in dynamic bone remodelling in the basal state. This is likely
a contributing factor to the lowered state of bone remodelling seen in hyperinsulinaemic
T2DM and CVD patients [45].
Hyperinsulinaemia/glycaemia mediated decreases in NAD+ availability, consequently
decreases antioxidants MnSOD2 and SIRT3 activity, this leads to a negative impact on
osteoblast differentiation [64]. Both MnSOD2 and SIRT3 are required to regulate mitochon-
drial stress, to enable cellular differentiation and bone formation [64]. MnSOD2 dismutes
mitochondrial superoxide, thus protecting complexes I and II of the mitochondrial electron
transport chain (ETC), where OxPhos occurs. Glucose restriction increases ketolysis, which
increases the redox span between complex I and III [54,65]. This decreases electron leakage
at these sites, which reduces the formation of superoxide. Glucose restriction concomitantly
leads to an increase in NAD+ dependent SIRT3 activity, which increases deacetylation of
MnSOD2 lysine residues: 53, 68 and 89 (K53, K68, K89), consuming NAD+ in the pro-
cess [56,57,66–69]. This consequently upregulates MnSOD2 antioxidant activity, resulting
in improved ROS management [70]. With improved ROS management and mt-OxPhos
capacity, due to glucose restriction and ketolysis, this maintains osteocytogenesis, viability
and connectivity. Maintenance of osteocyte viability knock-on effect results in sustained
dynamic bone remodelling, as well as regulation of osteoblast and osteoclast differentiation
and activity.
7. Glucose Restriction Increases Glutathione Activity and Improved Cell Viability
Glucose restriction decreases insulin signalling, thereby enabling increased beta-
oxidation and ketolysis, preserving NAD+ availability to enable upregulated SIRT3 activity
which increases NADPH production [71]. This drives increased glutathione reductase
activity, which increases the ratio of reduced to oxidised glutathione (GSH:GSSG). Thus
enhancing the intracellular antioxidant capacity to combat ROS damage (Figure 2) [72].
Calorie restriction decreases glucose and insulin levels, whilst increasing fatty acid oxi-
dation and ketogenesis. This is the metabolic phenotype of fasting. Mice under lower levels
of glucose and insulin show a marked increase in SIRT3 expression and activity, conse-
quently preventing age-related hearing loss, a condition associated with ageing, increased
hyperinsulinaemia, and osteofragilitas conditions [73]. In a mouse model, elevated insulin
and high glucose compromised mitochondria in osteocytes, increasing both cytoplasmic
and mitochondrial ROS, driving an inverse correlation between glutathione and mitochon-
drial ROS. Additionally, an increasing compromise in osteocyte mitochondrial-function
strongly correlates with increased impairments in skeletal health [74].
8. Glucose Restriction Enables Osteocytogenesis; Hyperglycaemia Inhibits It
Hyperglycaemia inhibits osteoblast differentiation into osteocytes, and reduces the
osteoblasts bone mineralisation capacity. In an in vitro model, IDG-SW3 cells differen-
tiated into osteoblasts were cultured in 1, 5 or 25 mmol/L of glucose, using an alizarin
red assay, it was shown that the osteoblasts cultured in the higher glucose concentration
had a decreased ability to form calcium deposits [37]. Furthermore, osteocytes cultured in
25 mmol/L of glucose, showed a decrease in osteoblast-to-osteocyte transition, assessed
using osteocytic Dmp-GFP gene expression reporter. A negative correlation was found
between glucose availability and osteocytogenesis, where osteoblast-to-osteocyte transition
increased as glucose concentration decreased, assessed via fluorescence microscopy/cell
sorting of Dmp-GFP expression. In short, glucose restriction increased osteocyte gene
expression [37]. These results indicate hyperglycaemia may disturb, if not diminish os-
teoblast and osteocyte replenishment potential. Hyperinsulinaemia and hyperglycaemia
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impair osteoblastogenesis, osteocytogenesis and osteoclastogenesis, resulting in decreased
dynamic bone remodelling. Patients with T2DM and CVD show marked decrease in bone
remodelling [7,51].
In a situation of hyperinsulinaemia which potentiates and consolidates hypergly-
caemia, osteoblast bone formation may become compromised over time, while osteoblast-
to-osteocyte transition is also diminished. In this scenario, one would expect less evidence
of bone mineralisation. However, if in the same hyperinsulinaemic and hyperglycaemic
state, the existing osteocytes are also producing elevated levels of mtROS, osteocyte death
would potentially incur vacancies in their lacunocanalicular space, which would result
in a state of heightened structural fragility. This may phenotypically appear as L-BMD
osteoporosis. However, hypothetically in a hyperinsulinaemic state, the “bone neurone”
sensory osteocyte makes a “margin-call” [25,75,76], to fossilize instead of leaving an empty
and thus structurally fragile space, so as to ensure structural rigidity at the very least.
Alternatively, the rationale may be simpler, where the osteocyte fossilisation occurs in
the hyperinsulinaemic state, so as to aid in mineral accretion during times recognised as
“feasting and energy abundance”. A plausible explanation would be hyperinsulinaemia
occurring in summer and autumn, when there is greater availability of high carbohydrate
foods, leading to increased levels and duration of insulin signals to the cells that there is a
food abundance period. Insulin mediates de novo adipogenesis, chronic insulin signals to
adipocytes to increase storage of fuel in the form of lipids (de novo lipogenesis) and to bone
cells to save minerals “for a rainy day”, in expectation of typically less food abundance in
winter. A similar physiological adaptation example for increasing storage of fuel, minerals
and vitamins, is during pregnancy, which has a natural state of mild hyperinsulinaemia,
in-order to provide for post-partum lactation [35,77].
Glucose restriction would historically normally occur during wintertime, with con-
comitant lowered insulin levels, as a result of decreased food abundance, especially the
farinaceous kind. A low glucose and low insulin environment would facilitate bone remod-
elling and improved resorption, as beta-hydroxybutyrate (BHB) inhibits mineralisation,
while acetoacetate activates mineralisation. Bone resorption increases either via increased
osteoclast activity, or higher levels of BHB which decreases the localised pH [78]. This
releases undercarboxylated osteocalcin (OCN), which would negatively regulate BHB
synthesis through its action on regulating basal insulin secretion [79,80]. This keeps ke-
tones in the physiologically healthy range [81]. The low glucose and insulin state that
facilitates dynamic bone remodelling, produces opened-up spaces for osteoblasts to then
begin matrix synthesis and renewed bone mineralisation activity. This is followed by
transition into a new generation of fresh osteocytes to maintain the newer sections of the
lacuna-canalicular network. However, if a glucose restriction phase does not occur, over
time the pre-osteoblast population may become compromised, whilst over-fossilisation
simultaneously occurs. Subsequent chronic hyperinsulinaemia induces excess osteocytic
ROS production to a degree that osteocytes are no longer able to actively inhibit minerali-
sation of their lacunocanalicular space, which is required to enable their survival, as well
as those they are further connected with. Combined, these effects may drive increasing
bone density, while making the bones both brittle and fragile.
9. Pyrophosphate and Sclerostin
Osteocytes produce pyrophosphate (ePPi), an inhibitor of mineralisation and car-
bonate solubiliser of bone mineral and matrix, thus regulating mineralisation and the
circulatory systemic levels of calcium and phosphate [82]. Hyperinsulinaemia increases
mtROS and cellular pathology, compromising osteocyte health, leading to mitochondrial
mediated living fossilisation of osteocytes within their lacunae. Magnesium-dependent
spherite-mediated osteocyte mineralisation provides evidence to support this, where higher
levels of magnesium are found in these micropetrosis fossilisation spaces formerly inhab-
ited by osteocytes [23]. This potentially traps/entombs magnesium within the living
fossilised bone; subsequently contributing to magnesium deficiency (MgD). Furthermore,
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MgD has its own effects on potentiating hyperinsulinaemia [83–85]. Culminating in a
vicious feedforward cycle.
While bisphosphonates are known to work at inhibiting osteoclast bone resorption,
they likely also work as an ePPi analogue. By assisting in inhibiting excessive mineralisation
of the osteocytes lacunae, helping to maintain fluid flow and osteocyte connectivity where
struggling osteocytes may fail to do so, thus saving the day in “assisting” the osteocytes in
their job to be able to regulate dynamic bone turnover, a marker of metabolic health [45,86].
A density threshold level of osteocytes is required to maintain homeostatic bone
remodelling, from sensing damage in-order to initiate repair processes [48], to mineral
storage during pregnancy or in preparation for a winter with decreased food availability.
Greater lacunae mineralisation has been detected with advanced age and/or untreated
osteoporosis. Increased lacunae calcium content coupled with poorer quality matrix,
contributes to increased bone brittleness and subsequent fragility [22,46].
Osteocytes synthesise sclerostin, a 22.5 kDa protein, which reduces osteoblast dif-
ferentiation, consequently downregulating bone metabolism. Although there is a clear
relationship between hyperinsulinaemia and sclerostin levels, further research is required.
Theoretically, a decreased osteocyte mass should predict lower sclerostin levels. However,
elevated sclerostin levels have been found in patients with CVD and chronic kidney disease
(CKD), two groups who typically have osteofragilitas. Furthermore, osteogenic differentia-
tion of vascular smooth muscle cells (VSMC) in CVD and CKD patients have been detected,
where there is an increase in expression of sclerostin in aortic valve tissue [87–90]. This
means caution is required when assessing bone and metabolic health via sclerostin levels.
10. Osteocytes Produce Alkaline Phosphatase
Alkaline phosphatase (ALP) is an extracellular membrane bound ectometalloenzyme
that catalyses the hydrolysis of inorganic pyrophosphate (PPi) to phosphate (Pi) at an
alkaline pH. Phosphate forms part of calcium hydroxyapatite crystals, and an increase in
phosphate promotes mineralisation. Gene mutation of tissue-nonspecific alkaline phos-
phatase (TNAP) results in hypophosphatasia under-mineralisation, demonstrating the
integral role of ALP in bone mineralisation [91].
Nucleotide pyrophosphatase phosphodiesterase (NPP1) inhibits the action of ALP by
increasing the concentration of calcification inhibitor pyrophosphate (ePPi) [70]. Insulin and
the fed-state reduces NPP1 gene (Enpp1) expression. Interestingly, fasting has been shown
to increase its expression. In short, fasting increases the concentration of ePPi via NPP1,
leading to inhibition of excessive mineralisation of the osteocyte lacunocanalicular space,
which results in maintaining osteocyte viability, dendritic connectivity and consequent
dynamic bone remodelling capacity. Insulin action leads to decreased ePPi concentration,
subsequently decreasing the osteocytes ability to inhibit bone mineralisation, thus increased
mineralisation of the osteocytes lacunocanalicular space occurs. The fasted state provokes
the opposite effect, inhibition of mineralisation, and potentially enhances physiological
levels of bone resorption via increased beta-hydroxybutyrate (BHB) [92].
If autumn were a time for humans to accumulate stored energy in preparation for
a fasting period during winter, where foods available during autumn increase insulin
secretion, activating energy storage mechanisms, logically mineral storage would also be
required and may also be facilitated via insulin’s action on inhibiting NPP1 production of
ePPi. This may provide an evolutionary explanation, where seasonal hyperinsulinaemia
propagates increased osteocyte-lacunae mineralisation during autumn, as an adaptive
survival mechanism. This would then be followed by a winter of fasting, which would
subsequently lead to increased NPP1 activity, relinquishing back into the system the stored
minerals. Hyperinsulinaemia T2DM could be described as a metabolic phenotype reflecting
a constantly “fed-state”, the ever-lasting autumn. Thus, providing an explanation of the
normal to increased BMD observed in people with T2DM.
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11. Osteocalcin
Patients with T2DM and insulin resistance have significantly lower levels of circulating
osteocalcin (OCN) than healthy controls [71,93–96]. OCN is a non-collagenous protein,
largely synthesized by osteoblasts and osteocytes that retain their expression of OCN [97].
Levels serve as a marker of osteoblast and osteocyte health. Serum OCN levels positively
correlates with: dynamic bone remodelling, decreased insulin resistance (IR), and reduced
T2DM and CVD risk [96,98–100]. Much published research show OCN increases insulin
secretion, with conclusions stating decreased OCN levels would result in decreased insulin
synthesis and secretion, and result in impaired glucose homeostasis. However, when
assessed in humans, low levels of OCN tracks with hyperinsulinaemia [96,101]. Ergo
providing evidence that production of high levels of insulin does not require high levels
of OCN.
12. Osteocalcin Endocrine Effects
Interestingly, OCN significantly increases insulin-independent glucose uptake, and
even more so in the presence of insulin. This leads to increased insulin sensitivity, through
reducing the amount of insulin required to facilitate glucose uptake [98]. Additionally,
OCN production increases the expression of mitochondrial uncoupling protein 1 (UCP1)
in adipocytes, leading to increased thermogenesis and mitochondrial biogenesis, thus
increasing glucose and fatty acid oxidation capacity. Furthermore, OCN increases adipocyte
production of adiponectin. However, caution is required when interpreting experiments
involving administering exogenous OCN in animal studies, in which these animals are
fed diets that do not induce hyperinsulinaemia (obesogenic for that species), that would
mimic the main human causal factor for T2DM. In the hyperinsulinaemic state, adiponectin
receptors Adr1/2 are downregulated [102]. The signalling dynamics and results elucidated
from animal studies in which exogenous OCN is provided to metabolically normal, or
genetically induced OCN deficient and/or OCN receptor KO mice, would likely not
be the same as what would occur in hyperinsulinaemic humans with low OCN. For
example, healthy insulin levels and insulin sensitivity plus exogenous OCn = X, whilst
hyperinsulinaemia and insulin resistance plus exogenous OCn = Y.
When wild-type mice (healthy) were administered exogenous OCN, their adipose
tissues were observed to have upregulated peroxisome proliferator-activated receptor
gamma coactivator 1-alpha (PGC1α) and adiponectin. Both adiponectin and PGC1α ex-
pression and activation, lead to increased beta-oxidation and correspond to improved
metabolism, insulin sensitivity and glucose homeostasis [103]. Effectively, metabolically
healthy mice respond in a physiologically normal way to the OCN. The elevated OCN in
this context, is thus able to further effect (positive feedforward) mechanisms that consoli-
date better glucose/fatty acid oxidation and ROS management. The marker then becomes
a maker of good health. OCN levels and the carboxylated-to-undercarboxylated ratio
(cOCN:ucOCN or Gla:Glu) act as surrogate markers of osteoblast and osteocyte health,
and consequently bone quality, which are then able to actively function in endocrine
homeostasis and metabolic health.
The effect of OCN on adipocytes include: improved insulin independent glucose up-
take, increased adiponectin synthesis and “energy wastage” through thermogenesis, and
decreased inflammatory cytokine production, leading to increased skeletal and muscular
insulin sensitivity [98]. Greater insulin sensitivity decreases the amount of insulin required
to achieve glucose homeostasis. Individuals who maintain normo-insulin levels via restrict-
ing carbohydrate intake, would likely maintain healthier osteoblasts and osteocytes. This
enables healthy endogenous OCN synthesis, as is seen in healthy controls. In the context of
normo-insulin and insulin sensitivity plus OCN, the result is X. Which is OCN increasing
adiponectin synthesis and signalling in a none hyperinsulinaemia and normoglycaemia
contextual environment. Furthermore, a reduced requirement and secretion of insulin,
decreases excessive mitochondrial ROS production and subsequent downstream cellular
pathophysiological adaptations.
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13. Carboxylation of Osteocalcin
Post translational modification alters OCN into one of 3 isoforms, which affects
bioavailability and activity of the bone-derived hormone. γ-carboxylation of OCN occurs
before secretion from osteoblasts and osteocytes. γ-glutamyl carboxylase (GGCX) enzyme
activity is dependent on availability of its cofactor vitamin K (in the reduced state), in order
to carboxylate OCN on glutamic acid residues: Glu17, 21 and 24. The carboxylated (cOCN
or Gla-OCN) form, is the most abundant form in bone extracellular matrix as carboxylation
increases OCN affinity for the mineral component of bone hydroxyapatite [79,98]. The
undercarboxylated and uncarboxylated forms, (ucOCN or Glu-OCN) are considered the
biologically active hormone isoforms. All three isoforms are present in the blood [39].
OCN concentration in human blood ranges between 10 to 40 ng/mL [39]. Interestingly,
in vitro experiments by Hill et al. show OCN in both carboxylated and uncarboxylated
forms are biologically active, both are able to modulate glucose uptake and increase insulin
sensitivity. However, the ucOCN form was more effective [98].
14. Osteocalcin and Insulin
Much research has shown that insulin signalling induces osteoblasts and osteocytes
to produce OCN and in vivo studies indicate that plasma OCN stimulates an increase in
pancreatic beta cell differentiation/proliferation via increasing cyclin D1, D2 and Cdk4 gene
expression, proteins involved in cell division [103]. Additionally, OCN directly and in-
directly via glucagon-like peptide-1 (GLP-1), increases insulin production capacity and
secretion upon glucose stimulus [103]. While this is shown in in vitro and animal studies,
T1DM patients who are given exogenous insulin should technically gain in increased
endogenous OCN synthesis, this would then be expected to stimulate pancreatic beta-cell
proliferation and subsequent endogenous insulin secretion capabilities. However, T1DM
patients do not appear to gain in the upregulation of endogenous insulin production. This
may be due to a lack of pancreatic precursor beta-cells, although it has been shown that
both T1DM and late-stage T2DM patients do have some functioning precursor pancreatic
beta-cells [100,104].
Wei et al. investigated the potential role of OCN as a means to stimulate pancreatic
beta-cell proliferation, given T1DM patients retain a small residual population of functional
beta-cells [104–106], the logic of their hypothesis seems plausible. T2DM patients have
low OCN levels too. However, this is with high insulin levels in non-insulin dependent
diabetes mellites (NIDDM). The question remains then, would these patients benefit from
exogenous OCN therapy? Or similar to conditions of T2DM, patients given exogenous
insulin, serves only to mask the downstream problem (hyperglycaemia), while increasing
hyperinsulinaemia and insulin resistance, driving the disease further [93,107]. If OCN in-
creases insulin secretion, then would we not see higher levels of OCN in hyperinsulinaemia
pathologies such as T2DM, CVD and MetS? On the contrary, those with normal insulin
levels have significantly higher OCN levels [93,107]. This may indicate OCN levels and
the carboxylation ratio, are firstly markers and then contributory makers of bone fracture
resistance, and metabolic and endocrine health.
Using a mouse model, Ferron et al. showed that intermittent injections of OCN
improved glucose metabolism, and increased skeletal mitochondrial content which led to
improved glucose and fatty acid oxidation capacity. Elevated OCN levels in the absence
of hyperinsulinaemia also increased energy expenditure, corroborating other research
showing OCN signalling via increasing adiponectin production, leads to increases in
brown fat UCP1, resulting in increased thermogenesis. As fat and glucose is oxidised
more efficiently, independent of insulin mediated glucose uptake, metabolic markers
consequently improve [108].
Evidence suggests the metabolic phenotype of low insulin and glucose levels facilitates
maintaining healthy osteoblasts and osteocytes, dendritic connectivity and maintenance of
the lacunae-canalicular network. This leads to the metabolic healthy phenotype of higher
levels of OCN synthesis and carboxylation capacity, resulting in fracture-resistant bone,
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with osteocytes maintaining basal bone remodelling. Furthermore, the resultant ability to
endogenously produce OCN, enables bone to participate in its endocrine-action on other
tissues and organs, further contributing to improved glucose homeostasis and insulin
sensitivity [109]. Restriction of dietary carbohydrate intake simultaneously maintains low
glucose levels and minimises additional exogenous stimulus on insulin secretion, thus
maintaining both markers in the low healthy physiological range.
15. cOCN Levels Determine Hydroxyapatite Alignment Formation
Moriishi et al. in PLOS Genetics, demonstrated using mouse model OCN knockouts of
the two mouse genes for OCN: Bglap and Bglap2, unlike humans who poses only one OCN
gene, that bone apatite crystallite alignment is dependent on carboxylated OCN [110]. In
the OCN-deficient mice, bone strength decreased, supporting the classical biology phrase—
structure dictates function. In this case, bone strength is determined by its structural quality,
which includes bone mass and quality of crystallite alignment with collagen fibres. These
structural features, combined, determine bone fracture resistance or osteofragilitas [111]. It
is important to note that Moriishi was not investigating OCN deficiency in the context of
hyperinsulinaemia, which likely would further contribute other detrimental factors, such
as poorer collagen synthesis and increased collagen glycation damage.
Hyperinsulinaemia and hyperglycaemia propagation of impaired osteoblastogene-
sis and osteocytogenesis results in decreased OCN production capacity, which impairs
hydroxyapatite crystallographic orientation to collagen fibrils. Combined with poorer
quality collagen synthesis and increased glycated collagen, the summative results may
lead to compounding effects on bone fragility via compromised structural quality, that is
independent of BMD. The sum of all of these dysregulated/impaired conditions, likely
leads to the increased fracture rates seen in patients with the T2DM hyperinsulinaemia-
osteofragilitas phenotype.
16. The Acute Stress Response
Responses to acute stress increases the ucOCN:cOCN (Glu:Gla) OCN ratio, this de-
creases OCN bone affinity, which reduces the well-formed structural alignment of hy-
droxyapatite that is needed for bone fracture resistance [110]. Elevated glucocorticoids
increase the synthesis of inflammatory cytokines and tumour necrosis factor α (TNFα).
Acute stress signals induce glutamate release from neurites, which competitively inhibits
GGCX, resulting in decreased post-translational modification-carboxylation of OCN in
osteoblastic lineage cells before cellular release [112,113]. The glutamate concentrations that
were shown to achieve this, were on par to that found in glutaminergic synapses [113,114],
which were able to cause osteoblasts to increases their release of ucOCN (Glu). This
downregulates parasympathetic tone and consequently allows sympathetic signals to be
propagated in the absence of suppression. Berger et al. demonstrated that intravenously
injected Glu-OCN into WT mice, caused an immediate and significant downregulation of
parasympathetic nervous system activity. This causes decreased contraction of the trachea
rings via GPRC6A receptor and acetylcholine signalling, with decreased gastrin levels and
increased heart rate [113].
Increased ucOCN (Glu) released due to the acute stress response (ASR), leads to
inhibition of parasympathetic tone via reducing acetylcholine (ACH) synthesis, release
and recycling [113]. Viewed from an evolutionary standpoint, in the event of potential
physical trauma, a high stress situation, which may result in a wound, in the insulin
sensitive state, the increased ASR inducing ucOCN (Glu) release may be evolutionarily
advantageous. ASR ucOCN (Glu) release may induce acute hyperinsulinaemia in-order to
effect multiple actions such as facilitating rapid skeletal muscle glucose uptake and aid
to inhibit anti-coagulation activity via elevating plasminogen activator inhibitor type 1
(PAI-1) thus disturbing fibrinolysis [53,115,116].
Acute hyperglycaemia provides extra glucose for skeletal muscle, and also increases
hepatic clotting factors and clotting activation [115], thus aiding in prevention of excessive
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blood-loss/haemorrhage from any potential wound and concomitant rapid hypotension
due to hypovolemia. Furthermore, elevated blood glucose due to glucocorticoid induced
hepatic glycogenolysis and gluconeogenesis, independently stimulates insulin secretion.
The ASR induces: acute hyperglycaemia that increases coagulation capacity, bone re-
lease of ucOCN (Glu) from osteoblast lineage cells and osteoclastic resorption, together
with hyperglycaemia and ucOCN (Glu) induced acute hyperinsulinaemia, which facili-
tates inhibition of the breakdown of clots. The plausible evolutionary purpose for this,
would be to help enable the stabilisation of wound clotting and thus prevent potentially
fatal haemorrhage.
17. Osteocalcin Regulation of Ketosis
Fasting increases ketogenesis and plasma BHB which increases bone resorption ability
via lowering the localised pH level as well as inhibiting/regulating osteoblast mineralisa-
tion activity [78]. This would increase plasma OCN levels that would go on to stimulate
pancreatic beta cell proliferation and insulin production capacity. Natural diurnal cortisol
signalling leads to hepatic glycogenolysis and release of glucose to the system, in turn
stimulating insulin secretion. Together, through BHB effect on OCN release, they provide
the stimulus for insulin secretion to act as a feedback mechanism to regulate ketogenesis.
OCN is considered to protect against obesity, improve glucose uptake
and enhance insulin sensitivity, either directly or via OCN stimulated adiponectin
secretion [97,100,103,117–119]. Osteocytes comprise the largest population of bone cells,
making them likely the biggest producer of OCN than is currently understood. Logically,
a substantial loss of osteocytes would result in decreased OCN production and lead to
subsequent increases in adiposity. This phenotype is seen in HI/T2DM/CVD patients,
who have lower plasma OCN and adiponectin, with increased or normal BMD. Bone
mineralisation is possible without OCN and may be enhanced in the hyperinsulinaemic
state [110]. Micropetrosis/living-fossilisation of the osteocytic lacuna-canalicular has been
demonstrated to be increased in hyperinsulinaemia pathologies [22,23,25,28]. BHB me-
diated inhibition of mineralisation may be analogous to ePPi and bisphosphonates that
help osteocytes maintain their lacunocanalicular network. Inhibition of lacunocanalicular
mineralisation concurrent with maintaining osteocyte viability, results in correctly-formed
fracture resistant bone that is also dynamically remodelled, a function of healthy bone
metabolism leading to wider effects on whole body metabolism.
18. Osteocalcin and Insulin Resistance/Hyperinsulinaemia
In vitro and in vivo KO studies, and studies administering exogenous OCN either
orally or intravenously to mice or rats, present results that suggest unOCN (Glu) is neces-
sary for pancreatic beta-cell proliferation. OCN is recognised and activates the GPRC6A
receptor on pancreatic beta cells [93,120]. This receptor has other ligands; therefore, caution
should be applied in interpreting results from genetic GPRC6A receptor KO studies. For
example, with Gprc6a-/- mouse pancreatic beta-cells, knocking out the receptor may have
potentially also ablated the role of other ligands in activating this promiscuous receptor
and its subsequent downstream intracellular signal cascades. Consequently, there is a
possibility of producing different combinatory cell signal results based on ligand type [121].
Furthermore, OCN crosses the blood-brain barrier, and studies have shown a brain target
receptor of OCN is Gpr158. However, it is likely that this is not the only brain OCN receptor,
as studies have shown areas of brain that do not express Gpr158 whilst still having OCN
activity, indicating other receptors at play [100].
In a mouse study, KO of beta-cell Gprc6a-/- gene expression which encodes the GPRC6A
protein receptor, rendered the beta-cells unable to produce sufficient insulin. As a re-
sult, these mice had metabolic abnormalities with a similar phenotype to Ocn-/- KO
mice [98,104,120]. However, as the GPRC6A receptor is able to be activated by other
ligands, absence of the receptor does not necessarily mean that a lack of ucOCN (Glu) sig-
nalling induces the metabolic abnormality. It may be due to the KO inadvertently rendering
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other ligands to be unable to signal the beta-cells via the “universal multiligand” GPRC6A
receptor [121]. An example of the conflicting information from these in vitro and in vivo
model studies is found in humans with hyperinsulinaemia pathologies. In these conditions,
studies have shown there is a significant inverse correlation between serum OCN levels
and: fasting insulin and glucose, BMI, HOMA-IR, leptin and triglycerides (p < 0.001), while
higher OCN levels positively correlates with adiponectin levels (p < 0.001) [93,98]. These
real-world investigations appear to contradict the animal model studies, which expect
lower OCN levels to predict lower insulin secretion.
Osteocalcin exerts a large amount of its effects via adiponectin [98]. However, under
high insulin conditions, adiponectin receptors are downregulated via insulin activating the
PI3K/FOXO1 signal transduction pathway. This diminishes the osteocalcin/adiponectin
induction of 5’ adenosine monophosphate-activated protein kinase (AMPK), PGC-1α,
mitochondrial biogenesis and increased thermogenesis, that all act to facilitate glucose
uptake and oxidation independent of insulin [102].
19. Vitamin D and Magnesium
Vitamin D is required for osteocyte viability and dendrite connectivity [44]. Hyper-
insulinaemia reduces vitamin D availability by increasing sequestration of the lipophilic
hormone into adipocytes [122]. Patients with pathologies of hyperinsulinaemia, including
T2DM, CVD, obesity, MetS and metabolic cancers, are associated with having a lower
vitamin D status [95,123]. In addition, hyperinsulinaemia promotes magnesium deficiency
(MgD) which decreases vitamin D transport in the blood [84]. Hyperinsulinaemia de-
creases hydroxylation of inactive 25-OHD3-cacidiol to active 1,25(OH)2D3-calcitriol by low-
ering 1-alpha hydroxylase (CYP27B1) activity. Hyperinsulinaemia increases mitochondrial
(mt) ROS generation and NAD+ depletion, both decrease NADPH availability [20,56,57].
CYP27B1 activity is NADPH and Mg dependent [84,85,124]. Thus, hyperinsulinaemia de-
creases cellular capacity to activate vitamin D via lowering CYP27B1 hydroxylase activity.
Chronic hyperinsulinaemia dysregulated vitamin D metabolism negatively affects
osteocyte health and their subsequent ability to perform dynamic perilacunar remod-
elling [44]. A study investigating 783 young northern European males ages 20 to 29 years,
found a significant association in vitamin D deficiency with peak bone mass. In par-
ticipants that had inadequate vitamin D status, parathyroid hormone (PTH) levels and
bone-specific alkaline phosphatase (BAP) were higher [125]. Interestingly, a reduction in
pre-osteoblast beta-oxidation capacity leads to decreased parathyroid hormone (PTH) sen-
sitivity [126], a potential contributor to the elevated levels of PTH seen in HI/T2DM/CVD
patients [127,128].
With the increasing prevalence of pre/diabetes, overweight and obesity in children
and adolescents, there are serious implications in long-term health. The negative effect
of low vitamin D levels on osteocyte viability consequently negatively affects the OCN-
producing cell population; this results in wider implications in bone fracture resistance
and metabolic/endocrine health. Vitamin D insufficiency is common in the paediatric
population, and is shown to be both a marker and/or maker in increasing the risk of
developing pre-diabetes (phenotype 3, stage 1/2, [71]). Early lifestyle interventions that
improve vitamin D status, starting from childhood, may contribute to reducing rates of
low-energy fractures, and to improving longer-term metabolic health [129].
Insulin is required for healthy bone mineralisation, as seen in insulin insufficient
T1DM [130]. Puberty and pregnancy are two stages of development where a natural
state of hyperinsulinaemia occurs [77,131,132]. Hyperinsulinaemia enables increased
growth in bones during puberty, and mineral accretion during pregnancy, which may
be in the form of micropetrosis (osteocyte-lacunae mineralisation), to ensure adequate
provision of minerals for nursing offspring during lactation. These phases of life lend a
physiological adaptive explanation as to why we would see an increase in BMD in T2DM
hyperinsulinaemia [30,32,133]. However, puberty and pregnancy are for a limited duration
of time and come with either growth in bones (puberty), or lactation and subsequent
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resorption of bone minerals. Whereas T2DM hyperinsulinaemia may go undetected for
many years, a pernicious chronic elevation, leading to excessive micropetrosis and living
fossilisation. The resultant disconnecting of osteocytes from one another, impairs their
ability to: sense and transmit information, modulate one another, and directly/indirectly
modulate bone turnover [31,62,134]. This hypothesis provides a plausible explanation as
to why we would see normal to H-BMD in T2DM not conferring fracture resistance.
Rolvien et al., found a 43% greater decrease in empty lacunae fraction with a de-
crease in the number of viable osteocytes in vitamin D deficient versus replete human
iliac crest biopsies (p < 0.001) [44]. Given that hyperinsulinaemia decreases vitamin D
availability, activation and transport, this is likely to profoundly influence osteocyte di-
rected bone remodelling, as osteocyte viability and thus population is vitamin D dependent.
Interestingly, osteocytes express the CYP27B1 enzyme, and are able to directly activate
25(OH)D3-calcidiol to 1,25(OH)2D3-calcitriol, providing a localised refined control in provi-
sion of active vitamin D availability. One of calcitriol’s many roles is to regulate/suppress
nuclear factor-kB (NFkB) pathway signalling in the adaptive immune system [135,136].
Theoretically, given osteocytes modulate osteoclastogenesis from the myelopoietic mono-
cyte/macrophage cell lineage, it stands to reason that their ability to directly activate
vitamin D serves to locally modulate/fine tune NFkB signalling, which would function in
the regulation of osteoclastogenesis. However, this needs to be investigated further.
20. Hyperinsulinaemia Decreases Vitamin D Availability, Decreasing Osteocalcin Synthesis
Bioactive 1,25(OH)2D3-calcitriol stimulates OCN transcription. Vitamin D response
elements are found within the osteoblast/osteocyte 600-nucleotide OCN gene regulatory-
sequence transcription start site [137]. Hyperinsulinaemia increases de novo lipogenesis,
and drives lipophilic vitamin D to be accreted into adipocytes [122], decreasing availability.
Vitamin D deficiency favours osteocyte apoptosis and reduced osteocyte connectivity,
decreasing their viability further. Osteocyte connectivity is essential for their function in
healthy bone remodelling, and to effect regulation of OCN production [44,135,138,139].
The osteocytes expression of CYP27B1, enabling localised direct activation of calcidiol
to calcitriol [41,136], arguably facilitates osteocyte regulation of osteoblastic OCN produc-
tion. Increased presence of differentiated osteocytes positively correlates with gene expres-
sion of OCN in osteoblasts, indicating osteocyte control of osteoblast OCN synthesis [140].
If osteocyte population/health is compromised, this may in turn compromise osteoblast
OCN production. A cross-sectional study of 191 non-osteoporotic postmenopausal women
found a significant negative correlation between serum OCN and insulin resistance (IR)
and HbA1c, p = 0.001 and p = 0.048 respectively [95]. Hyperinsulinaemia patients have
lower serum OCN levels than healthy persons, supporting this notion. However further
investigations are needed.
21. Vitamin K, Osteocalcin Carboxylation and Hydroxyapatite Crystallite Alignment
Hyperinsulinaemia mediates de novo lipogenesis and adipogenesis, inhibits lipolysis,
and drives adipocyte vitamin K sequestration [95]. This leads to decreased vitamin K avail-
ability for OCN carboxylation. Vitamin K1 sequestration into adipocytes is found in higher
concentrations in adipose tissue. The reduced form of vitamin K1 is an essential co-factor
for the γ-glutamyl carboxylase enzyme, to carboxylate OCN [112]. Children who have
suffered low energy fractures versus never-suffered-fractures controls, have significantly
lower levels of serum carboxylated OCN to uncarboxylated (cOCN:ucOCN) [117]. This
corroborates OCN requirement for hydroxyapatite crystallite alignment with collagen for
bone quality, which includes the mineralisation structural formation as well as BMD, which
translates into fracture resistance [99,110].
Lower levels of vitamin K has also been found to be negatively correlated with ucOCN
(Glu) levels in healthy women, where elevated ucOCN (Glu) is a known risk factor for
increased fracture risk [141]. In a double blinded, randomised controlled trial with T2D
patients, n = 40, between 30 to 70 years of age, patients were assigned to one of three
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groups: (a) placebo-a, n = 16, 1000 IU vitamin D3 + calcinated magnesium, (b) placebo-b,
n = 12,100 ug vitamin K2 + calcinated magnesium and (c) the intervention group, n = 12,
1000 IU vitamin D3 + 100 ug vitamin K2. The vitamin D3 group had a significant decrease
in serum ucOCN (Glu) 3.3 ± 1.7 ng/dL to 2.5 ± 1.5 ng/dL (p = 0.026), ucOCN:cOCN
(Glu:Gla) ratio 7.0 ± 7.0 to 3.1 ± 1.7 (p = 0.039), glucose (p < 0.001) and pancreatic beta
cell percentage function (p = 0.041). The vitamin K2 group saw a significant decrease
in glycaemia (p = 0.002), pancreatic beta cell functional percentage (p = 0.039), HOMA-
IR (p = 0.041) and a significant increase in cOCN (Gla) from 0.818 ± 0.567 ng/dL to
1.2 ± 1.1 ng/dL (p = 0.041). The group receiving both vitamin D3 and K2, saw a significant
decrease in glycaemia (p = 0.002) with a decrease in pancreatic beta cell function (p = 0.004),
and a significant decrease in ucOCN:cOCN (Glu:Gla) from 6.4 ± 4.2 to 4.3 ± 2.9 ratio
(p = 0.023) [101]. An interesting aspect of this is the decrease in glycaemia in the context
of a decrease in functional pancreatic beta cells, which seems counter-intuitive. This
indicates decreased reliance on insulin for glucose homeostasis, which supports other
studies that show both cOCN and ucOCN are biologically active and have a functional role
in insulin-independent glucose uptake. In addition to increasing adipocyte and myocyte
mitochondrial biogenesis and uncoupling proteins, leading to increased thermogenesis,
likely via stimulating adiponectin synthesis [98].
22. Glycation Damage Decreases Vitamin K-Dependent Carboxylation of Osteocalcin
As described earlier, cOCN is required for healthy bone matrix hydroxyapatite crys-
tallite alignment, which confers structural integrity to bone that decreases fracture risk.
Carboxylation of OCN is mediated by the vitamin K dependent γ-glutamyl carboxylase
enzyme [112]. Lipophilic vitamin K is transported via chylomicron remnants (CR) in
the plasma [142]. Osteoblasts and osteocytes express the membrane receptor proteins
apolipoprotein E (apoE) and LDL receptor related protein 1 (LRP-1). A ligand for osteoblast
LRP-1 is the CR apoE protein. Osteoblasts are thus able to take up CR containing vitamin K
via LRP-1 recognition and binding with the CR structural apoE protein leading to receptor
mediated endocytosis. LRP-1 recognition of apoE is via the heparan sulfate proteoglycan
(HSPG) mediated pathway [143,144]. Uptake of CR cargo: vitamin K and dietary lipids,
are required for osteoblasts’ high metabolic demand. Hyperinsulinaemia negatively im-
pacts HSPG function and availability, via impairment of vitamin D regulation. Vitamin D
regulates sulfate synthesis, required for heparan sulphate [145].
Neimeier et al. demonstrated in a murine in vivo model that osteoblast internalisation
of CR, requires osteoblast membrane expression of endogenous apoE in order to tether
CR in the first steps of endocytosis uptake. This occurs in a similar secretion-recapture
mechanism performed by hepatocytes [142]. ApoE is highly susceptible to sugar moieties
irreversibly attaching to NH2-protein groups. This glycation damage interferes with CR
attraction, receptor recognition and lipid-binding ability [144,146], and ultimately prevents
the uptake of CR carrying vitamin K and fatty acids to osteoblasts.
23. Hyperinsulinaemia Decreases Heparan Sulphate Proteoglycans
Heparan sulphate proteoglycans are robust anticoagulants, buffering glycation dam-
age. An increase in heparanase and a decrease in heparin sulphate is implicated in en-
dothelial cell dysfunction [147]. Heparanase is an endoglycosidase that enzymatically
cleaves glycosaminoglycan heparan sulphate [148]. Hyperglycaemia oxidative damage,
resulting in AGE, and receptor for AGE (RAGE) production, increases heparanase expres-
sion [147,149]. Heparan sulphate is required for adipocyte to macrophage mitochondrial
transfer, which is decreased in hyperinsulinaemia/obesity [150]. Hyperinsulinaemia drives
lowered vitamin D hydroxylation/activation/transport, increasing sulphate wastage and
oxidation damage to heparin sulphate proteoglycans [145]. The multiple mechanisms by
which hyperinsulinaemia and hyperglycaemia decrease extracellular-localised heparan
sulphate, contribute to impairing osteocytes and osteoblast uptake of CR cargo, includ-
ing essential fatty acids for fuelling and vitamin K. These further drive cellular reliance
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on glucose fuelling, in turn depleting NAD+ and increasing ROS. Perlecan is a form of
heparan sulphate proteoglycan that is essential in positioning, anchoring and receiving
mechano-stimuli for osteocytes in their lacunocanalicular space. Hyperinsulinaemia and
hyperglycaemia driven breakdown of HS via increased heparanase enzymatic cleavage and
increased sulphate wastage, results in decreasing osteocyte perlecan, further contributing
to harming osteocyte viability and function [31,62].
Thus the “perfect storm” is established in hyperinsulinaemia osteofragilitas, with
increased glycation damage to: collagen rendering it rigid and unrecognisable to digestion
enzymes, the vasculature causing increased hypoxia, and to apoE proteins that are essential
for receptor mediated uptake of vitamin K. Without vitamin K, osteocalcin carboxylation
status decreases, resulting in disordered hydroxyapatite crystallite formation and conse-
quent increased bone fragility irrespective of BMD. Furthermore, glycation damage to
apoE and HSPG would decrease delivery of fatty acids for the high metabolic demands
required for osteoblast collagen synthesis and osteoblasto/cytogenesis. Impaired fatty acid
delivery, along with insulin-mediated inhibition of beta-oxidation and increased mtROS
generation, consequently drives poorer collagen production and decreased OCN synthe-
sis. With reduced ability to access fatty acids for fuel, concomitant to increased hypoxia,
osteoblasts and osteocytes are forced to be more reliant on glucose oxidation, leading to
increased mtROS production, which decreases osteocytogenesis and osteocyte dendritic
connectivity [59]. Dynamic bone remodelling decreases and a vicious cycle ensues.
24. OCN and the Brain
OCN protects against neural apoptosis and enhances hippocampus neurogenesis.
OCN has been shown to induce changes in GABA and neurotransmitter gene expression,
decreasing GABA and increasing serotonin and dopamine, ameliorating anxiety and
depression, and improving learning capacity [151]. Oury et al. showed in mice studies and
in ex vivo and explant studies; OCN affects neurotransmitter gene expression in the brain.
They cleverly demonstrated that OCN passes through the BBB. OCN mediates these neural
effects via a different receptor to GPRC6A, as they conducted the same experiments in
Gprc6a-/- knockout and Ocn-/- mice. This study also showed administering of OCN rescued
the neurological effects in learning. Mice pups born to Ocn-/- mothers suffered significant
increased anxiety, depression and loss of learning capability. Furthermore, neurogenesis
was negatively affected. The ability to learn was assessed via the Morris Water Maze test
(MWM), which is considered a test that measures the function of the hippocampus. Mice
born from Ocn-/-, WT, Esp-/- mothers were tested 4 times a day for 10 days. The Ocn-/-
mice results showed that, over the 10 days of “exposure to the activity,” they were almost
completely unable to learn [151].
Khrimian et al. provides evidence that OCN positively regulates hippocampal-
dependent memory by activating the inositol 1,4,5-triphosphate (IP3) intracellular signal
transduction cascade via binding to neuronal Gpr158 in the CA3 region of the hippocam-
pus [152]. This area of research is in its infancy and warrants further investigation, given
the increase in cognitive decline, Alzheimer’s disease (AD) and Parkinson’s disease (PD)
that are increasingly recognised as conditions of hyperinsulinaemia and mitochondrial
distress [153–155]. Increasing evidence is demonstrating a role of OCN in neurological
health and disease [109,156,157]. This leads to further concerns with the increasing earlier
rates of obesity, T2D and hyperinsulinaemia in women. Evidence suggests that maternal
OCN levels may impact embryonic neurogenesis and rescue from apoptosis, leading to
long term effects on offspring such as anxiety, depression and learning capacity [151].
AD and PD are associated with significant increased rates of fragility fractures, further-
more, fragility fractures are also associated with an increased rate in the development of
dementia [158–161].
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25. Osteocalcin Affects Satiety Regulation and Hepatic Glucose Output
OCN increases serum glucagon-like peptide-1 (GLP-1) levels [162]. GLP-1 suppresses
pancreatic α cell secretion of glucagon leading to glycaemia regulation (decreasing hepatic
glucose output). GLP-1 also slows gastric emptying leading to increased nutrient absorp-
tion, and inhibits food intake [163]. The slowing of gastric emptying and inhibition of food
intake by GLP-1 is mediated via vagal circuits, as this effect was shown to be abrogated
after truncal vagotomy in normal weight none-diabetic men [164].
OCN further modulates pancreatic α cell secretory profile via regulating gene expression
of the rate limiting enzyme tryptophan hydroxylase (Tph) for serotonin (5-hydroxytryptamine)
synthesis from 5-hydroxytryptophan (5-HTP) [151,154,165–168]. Under high and low
glucose settings, the pancreatic alpha cell glucagon secretion decreases when serotonin
levels are higher [71,168]. OCN levels are higher in healthy individuals and lower in
people with T2D. This is potentially a contributory factor in lost-inhibition on glucagon
secretion, therefore leading to increased hepatic glucose output observed in T2 diabetics.
The consequent higher set point of hepatic glucose output, feeds forward in generating
higher rates of glycation damage and hyperinsulinaemia.
Interestingly, OCN survives the digestive tract intact and is biologically active in
the gut. Mizokami et al. demonstrated in mice, that oral ingestion of OCN was more
effective at maintaining serum GLP-1 levels than via intraperitoneal injection. The digestive
form likely works without absorption via stimulating GPRC6A on the apical side of the
intestinal enterocytes, to stimulate synthesis of GLP-1, without the need to enter into the
blood stream [162]. GLP-1 is rapidly degraded by cell-surface aminopeptidase dipeptidyl
peptidase IV (DPPIV) [163]. Around 4% of oral OCN is absorbed into the blood stream,
and raises serum GLP-1 as much as intravenous injection [162]. It may be that OCN action
within the gut, on the apical surface side of epithelial cells works in addition to basal side
activation, effectively sustaining synthesis for a longer duration of time, independent of
raising serum OCN levels. GLP-1 agonists are currently an exciting area of research in the
management of T2DM, aiding in decreasing hepatic glucose output.
26. Laboratory Identification
Patients presenting with low energy fracture(s) and normal to higher BMD should be in-
vestigated for T2DM and hyperinsulinemia. Furthermore, identification of hyperinsulinaemia-
osteofragilitas before fracture occurrence will enable earlier intervention, and provide better
patient understanding and compliance with clinical nutritional management. Laboratory
identification biomarkers to be evaluated include: fasting insulin, glucose, BHB, OCN
(ideally the cOCN:ucOCN ratio to be included), glucagon, GLP-1 and serotonin. If BHB
levels are below 0.1 mmol/L and OCN levels are on the lower end or below the reference
range, a 5-h OGTT with insulin sensitivity assay in-order to determine Kraft pattern and
metabolic phenotype is advised [16,71].
An effective method to decrease excess insulin exposure whilst simultaneously im-
proving glucose homeostasis, for hyperinsulinaemia with or without hyperglycaemia, is
through lifestyle management. Carbohydrate restriction with adequate individualised
support, should be considered the first line of treatment [53,169,170], with further focus on
a diet that maximises nutrient density, especially: vitamin D3, K and magnesium.
27. Conclusions
Micropetrosis/living fossilisation increases with age. Further investigations need
to be conducted into the presence and degrees of micropetrosis in hyperinsulinaemia-
osteofragilitas. Furthermore, hyperglycaemia decreases osteoclastogenesis [7], which
would inhibit the bone resorption that is necessary to effect bone remodelling, which
would include the need for removal of glycated collagen and micropetrotic bone. However
glycated collagen is rendered unrecognisable by enzymes for breakdown [47]. In addition
to increased glycation of HbA1c and collagen in hyperinsulinaemia T2DM, MetS and CVD
patients [146], there is also increased glycation of their ApoE and ApoB lipoproteins [146].
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This renders chylomicron remnants carrying vitamin K, unable to be recognised by LRP-
1 receptors on osteoblast and osteocytes [142]. Carboxylation capacity will be decreased
as a result of reduced vitamin K dependent γ-glutamyl carboxylase activity, along with
increased bone fragility and fracture risk due to poorer structural alignment of bone hy-
droxyapatite, which is dependent on carboxylated OCN status [110]. Osteocytes synthesize
OCN and directly control osteoblast OCN synthesis. Osteocyte dendritic connectivity
and viability, and their capacity to maintain the lacunocanalicular fluid-filled network is
evidently essential, in order for them to perform their role in orchestrating and regulating
dynamic bone remodelling. This is not only a marker and maker of healthy bone, but is
also increasingly appearing as a key endocrine player in whole body metabolism, as well
as many homeostatic feedback loops.
Pregnancy and seasonal feasting (autumn where fruit would be more abundant)
are two natural events are recognised to induce a period of physiological hyperinsuli-
naemia [77], where it is plausible to reason that the hyperinsulinaemia phenotype would
not only enable the increase in adipogenesis for energy storage, but also facilitate vitamin
and mineral storage. Hyperinsulinaemia drives increased adipocyte sequestration of vi-
tamin D and K. Vitamin D is required for osteocyte viability and dendritic health, and
to regulate OCN synthesis. Healthy osteocytes synthesise OCN and stimulate osteoblast
OCN synthesis. The carboxylation status of OCN is dependent on vitamin K availability.
Hyperinsulinaemia decreases vitamin K circulation availability, whilst the increased gly-
cation to proteins occurring in hyperinsulinaemic and hyperglycaemic patients renders
vitamin K delivery and uptake via CR apoE/LRP-1 receptor-mediated uptake seriously
impaired. Consequently, less OCN is synthesised and less is carboxylated, resulting in
poorly formed bone hydroxyapatite crystallite alignment, yet not necessarily compromis-
ing BMD, resulting in hyperinsulinaemia-osteofragilitas. Furthermore, glycation damage
is incurred on existing bone type 1 collagen, rendering it stiffer and unrecognisable to
digestive enzymes. Glycation-induced inhibition of CR fatty acid delivery to osteoblasts
and osteocytes results in decreased beta-oxidation, which is needed for the high energy
demand for collagen synthesis—at the same time, increasing mtROS production due to an
increased reliance on glucose-derived ATP synthesis, which depletes intracellular NAD+.
This decreases mitochondrial antioxidant enzyme synthesis, culminating in the production
of poorer quality collagen.
Both seasonal diet-induced hyperinsulinaemia and the time limited duration of preg-
nancy hyperinsulinaemia increase osteocyte spherite-mediated living fossilisation, thus
entombing the osteocytes along with magnesium and other minerals within bone, increas-
ing BMD in the process. In a healthy natural cycle, winter follows autumn and lactation
follows pregnancy, where minerals would need to be released back into the system. How-
ever, chronic hyperinsulinaemia is a situation where winter never comes. The continual
stimulant of insulin secretion largely due to dietarily derived farinaceous carbohydrates,
perpetuates the physiological condition into a pathological condition as threshold limits
are passed, such as the degree in loss of osteocytes and degree of living fossilisation of their
lacunocanalicular system, that may no longer be easily recoverable. The consequences are
further reaching than simply bone fracture resistance, as we are increasingly discovering
bone’s role in cardiovascular, muscular, renal and potentially neurological health. Keeping
bone healthy has much wider implications in chronic diseases and the ageing process.
Evidence suggests that carbohydrate restriction that maintains a healthy low insulin and
glucose level, also positively maintains the viability of osteocytes and osteoblasts, that
orchestrate dynamic bone remodelling, bone strength and fracture resilience. In turn,
maintaining healthy osteocytes, likely feeds forward in positively modulating neurological,
endocrine and metabolic health.
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